source clinicalSource Clinical is an invaluable guide to the clinical research services sector, supporting pharmaceutical and biotechnology companies with the information they need to progress their drug candidates through the clinical development process.

Source Clinical comprises an extensive compilation of information on companies with the expertise to support and manage clinical research including suppliers of clinical trial quantities of drug products, contract test laboratories, operators of clinical research facilities and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

Through its comprehensive coverage, and with the support of One Nucleus and Bionow, Source Clinical is the reference tool supplying essential information that streamlines the clinical research partner selection process.

Bio-Rad introduces antibodies to support inflammatory bowel disease and Crohn’s disease research

Bio Rad antibodies 26.6.18Bio-Rad Laboratories, Inc has launched a range of anti-vedolizumab antibodies to be used to support research into the treatment of ulcerative colitis (inflammatory bowel disease) and Crohn’s disease. Vedolizumab (Entyvio) is a monoclonal antibody used to treat these diseases and Bio-Rad’s anti-vedolizumab antibodies include four recombinant monoclonal anti-idiotypics that are highly specific for this humanised IgG1 kappa drug, making them highly suitable for the development of bioanalytical and patient monitoring assays.

The anti-vedolizumab antibodies are generated using Bio-Rad’s Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display, resulting in highly targeted reagents. These paratope-specific antibodies inhibit the binding of vedolizumab to its target, alpha4beta7 integrin, which makes them ideal for development of a pharmacokinetic bridging ELISA to monitor free drug levels, or as reference standards in anti-drug antibody assays. In addition, their recombinant production method ensures a consistent and secure supply.

The new antibodies are approved for in-vitro research purposes and for commercial applications for the provision of in-vitro testing services to support preclinical and clinical drug development and patient monitoring.

For further information about Bio-Rad visit

Last modified onTuesday, 26 June 2018 04:56